[1] 周家琛, 郑荣寿, 张思维, 等. 2000—2015年中国肿瘤登记地区食管癌发病及年龄变化趋势[J]. 中华肿瘤防治杂志, 2020, 27(18): 1437-1442. [2] 邵丽华, 张秋宁, 田金徽, 等. 食管癌临床指南和共识的质量评价[J]. 中国循证医学杂志, 2020, 20(5): 593-603. [3] 王程浩, 韩泳涛. 2020年中国临床肿瘤学会《食管癌诊疗指南》解读[J]. 肿瘤预防与治疗, 2020, 33(4): 285-290. [4] IGNACIO R M C, DONG Y L, KABIR S M, et al. CXCR2 is a negative regulator of p21 in p53-dependent and independent manner via Akt-mediated Mdm2 in ovarian cancer[J]. Oncotarget,2018, 9(11): 9751-9765. [5] DOBRESCU R, PICU C, CARAGHEORGHEOPOL A, et al. Serum matrix metalloproteinase-9(MMP-9) can help identify patients with papillary thyroid cancer at high risk of persistent disease: Value and limitations of a potential marker of neoplasia [J]. Cancer Biomark, 2020, 29(3): 337-346. [6] CHEN L, LIN G X, CHEN K H, et al. VEGF promotes migration and invasion by regulating EMT and MMPs in nasopharyngeal carcinoma[J]. J Cancer, 2020, 11(24): 7291-7301. [7] AHMED O, AJANI J A, LEE J H. Endoscopic management of esophageal cancer[J]. World J Gastrointest Oncol, 2019, 11(10): 830-841. [8] CODIPILLY D C, QIN Y, DAWSEY S M, et al. Screening for esophageal squamous cell carcinoma: recent advances[J]. Gastrointest Endosc, 2018, 88(3): 413-426. [9] SPATARO J, ZFASS A M, SCHUBERT M, et al. Early esophageal cancer: a gastroenterologist's disease[J]. Dig Dis Sci, 2019, 64(11): 3048-3058. [10] HA H, DEBNATH B, NEAMATI N. Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases[J]. Theranostics, 2017, 7(6): 1543-1588. [11] CUI D, ZHAO Y, XU J. Activated CXCL5-CXCR2 axis promotes the migration, invasion and EMT of papillary thyroid carcinoma cells via modulation of β-catenin pathway[J]. Biochimie, 2018, 148: 1-11. [12] TANAKA K, YOSHIMURA C, SHIINA T, et al. Generation and characterization of inhibitory antibodies specific to Guinea pig CXCR1 and CXCR2[J]. Monoclon Antib Immunodiagn Immunother, 2017, 36(2): 44-49. [13] GAO Y, GUAN Z F, CHEN J Q, et al. CXCL5/CXCR2 axis promotes bladder cancer cell migration and invasion by activating PI3K/AKT-induced upregulation of MMP2/MMP9[J]. Int J Oncol, 2015, 47(2): 690-700. [14] MONDAL S, ADHIKARI N, BANERJEE S, et al. Matrix metalloproteinase-9(MMP-9) and its inhibitors in cancer: a minireview[J]. Eur J Med Chem, 2020, 194: 112260. [15] WU M H, TZENG H E, WU C N, et al. Association of matrix metalloproteinase-9 rs3918242 promoter genotypes with colorectal cancer risk[J]. Anticancer Res, 2019, 39(12): 6523-6529. [16] CHEN L, LIN G X, CHEN K H, et al. VEGF promotes migration and invasion by regulating EMT and MMPs in nasopharyngeal carcinoma[J]. J Cancer, 2020, 11(24): 7291-7301. |